Clinical Effect of Shugan Hewei Prescription Combined with Vonoprazan on Refractory Gastroesophageal Reflux Disease Due to Qi Depression and Phlegm Obstruction

QI Mei; ZHOU Yue; ZHANG Mengyuan; WANG Yi; WANG Hongwei; ZHENG Qinwei; FANG Shengquan

doi:10.13422/j.cnki.syfjx.20240399

您当前的位置：

首页 >

文章列表页 >

Clinical Effect of Shugan Hewei Prescription Combined with Vonoprazan on Refractory Gastroesophageal Reflux Disease Due to Qi Depression and Phlegm Obstruction

更新时间：2023-11-20

- Clinical Effect of Shugan Hewei Prescription Combined with Vonoprazan on Refractory Gastroesophageal Reflux Disease Due to Qi Depression and Phlegm Obstruction
  增强出版
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 24, Pages: 146-154(2023)
- 作者机构：
  
  上海中医药大学附属岳阳中西医结合医院，上海 200080
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20240399
  CLC： R2-0;R22;R285.5;R2-031;R287;R573.9
- Published：20 December 2023，
  
  Published Online：07 November 2023，
  
  Received：26 May 2023，
- 稿件说明：
扫描看全文
齐梅,周悦,张梦圆等.疏肝和胃方联合伏诺拉生治疗气郁痰阻型难治性胃食管反流病的临床疗效[J].中国实验方剂学杂志,2023,29(24):146-154.

QI Mei,ZHOU Yue,ZHANG Mengyuan,et al.Clinical Effect of Shugan Hewei Prescription Combined with Vonoprazan on Refractory Gastroesophageal Reflux Disease Due to Qi Depression and Phlegm Obstruction[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(24):146-154.
齐梅,周悦,张梦圆等.疏肝和胃方联合伏诺拉生治疗气郁痰阻型难治性胃食管反流病的临床疗效[J].中国实验方剂学杂志,2023,29(24):146-154. DOI： 10.13422/j.cnki.syfjx.20240399.

QI Mei,ZHOU Yue,ZHANG Mengyuan,et al.Clinical Effect of Shugan Hewei Prescription Combined with Vonoprazan on Refractory Gastroesophageal Reflux Disease Due to Qi Depression and Phlegm Obstruction[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(24):146-154. DOI： 10.13422/j.cnki.syfjx.20240399.

摘要

目的

评价“疏肝和胃方”联合伏诺拉生治疗气郁痰阻型难治性胃食管反流病（RGERD）的临床疗效与可能存在的不良反应。

方法

将符合纳入标准的80例RGERD患者均进行24 h pH阻抗与高分辨率食管测压及电子胃镜检查；通过随机数字表将80例RGERD患者随机分配到观察组与对照组，观察组给予中药疏肝和胃方（1袋/次，2次/d）联合伏诺拉生片（20 mg/次，1次/d）治疗；对照组予伏诺拉生片（20 mg/次，1次/d）治疗，两组患者治疗周期均为4周。观察两组患者临床疗效，治疗前、治疗2周后、治疗后中医证候（咽部不适如有痰梗、胸骨后不适、嗳气等）积分、躯体症状、生活质量及胃镜下食管黏膜改善情况。

结果

最终完成试验并纳入统计者75例，观察组38例，对照组37例。观察组临床总有效率为89.47%（34/38），对照组临床总有效率为62.16%（23/37）；观察组总有效率显著高于对照组，差异有统计学意义（

=13.014，

0.01）。与本组治疗前比较，两组患者食管黏膜评分、反流性疾病问卷评分、中医主证咽部不适如有痰梗及胸膺部不适评分、胃食管反流病生活质量评价量表（GERD-HRQL）、躯体症状自评量表（SSS）评分均明显降低（

0.05）；与对照组治疗后比较，观察组在缓解气郁痰阻型RGERD患者烧心、反酸、咽喉不适如有痰梗、胸骨后不适、嗳气、半夜呛咳、恶心干呕、口黏腻、失眠效果等临床症状、躯体化症状及生活质量方面效果更优（

0.05，

0.01），但治疗后组间比较两组食管黏膜改善情况差异无统计学意义。

结论

疏肝和胃方联合伏诺拉生治疗气郁痰阻型RGERD在临床症状、体征及生活质量、躯体化症状改善等方面效果更优，无明显不良反应。

Abstract

Objective

To evaluate the clinical efficacy and adverse effects of Shugan Hewei prescription combined with vonoprazan in the treatment of refractory gastroesophageal reflux disease （RGERD） due to qi depression and phlegm obstruction.

Method

Eighty RGERD patients who met the inclusion criteria underwent 24-hour pH impedance and high-resolution esophageal manometry and electronic gastroscopy. The 80 patients were randomly assigned to an observation group （Shugan Hewei prescription， one bag each time， twice a day + vonoprazan， 20 mg each time， once a day） and a control group （vonoprazan， 20 mg each time， once a day） by the random number table method. The treatment in both groups lasted for 4 weeks. The clinical efficacy was examined. The scores of TCM symptoms （pharyngeal discomforts such as phlegm obstruction， retrosternal discomfort， and belching）， somatic symptoms， quality of life， and improvement of esophageal mucosa under gastroscopy were observed in both groups before treatment and after treatment for 2 and 4 weeks.

Result

Seventy-five patients completed the trial were included in this study， including 38 patients in the observation group and 37 patients in the control group. The total response rate in the observation group was 89.47%（34/38）， which was higher than that （62.16%，23/37） in the control group （

=13.014，

0.01）. After treatment， the scores of esophageal mucous membrane， reflux disease symptoms， TCM symptoms， gastroesophageal reflux disease health-related quality of life scale （GERD-HRQL）， and somatic self-rating scale （SSS） decreased in both groups（

0.05）. Moreover， the observation group outperformed the control group in alleviating heartburn， acid reflux， throat discomforts， midnight coughing， nausea and dry vomiting， mucousy mouth， and insomnia in the patients with GERD （

0.05，

0.01）. However， the two groups showed no statistically significant differences in the improvement of esophageal mucosa after treatment.

Conclusion

The combination of Shugan Hewei prescription with vonoprazan was superior to vonoprazan alone in treating RGERD regarding clinical symptoms， physical signs， quality of life， and somatic symptoms， without causing obvious adverse effects.

关键词

难治性胃食管反流病疏肝和胃方伏诺拉生疗效评价

Keywords

refractory gastroesophageal reflux diseaseShugan Hewei prescriptionvonoprazanefficacy evaluation

references

BAJBOUJ M.Diagnosis and therapy of atypical reflux symptoms when PPI therapy fails［J］.HNO，2012，60（3）：193-199.

RETTURA F，BRONZINI F，CAMPIGOTTO M，et al.Refractory gastroesophageal reflux disease：A management update［J］.Front Med （Lausanne），2021，8：765061.

ZERBIB F，BREDENOORD A J，FASS R，et al.ESNM/ANMS consensus paper：Diagnosis and management of refractory gastro-esophageal reflux disease［J］.Neurogastroenterol Motil，2021，33（4）：e14075.

MORAES-FILHO J P P.Refractory gastroesophageal reflux disease［J］.Arq Gastroenterol，2012，49（4）：296-301.

NAIK D，MEYERS M H，VAEZI M F.Treatment of refractory gastroesophageal reflux disease［J］.G&H，2020，16（4）：196-205.

IWAKIRI K，SAKURAI Y，SHIINO M，et al.A randomized，double-blind study to evaluate the acid-inhibitory effect of vonoprazan （20 mg and 40 mg） in patients with proton-pump inhibitor-resistant erosive esophagitis［J］.Therap Adv Gastroenterol，2017，10（6）：439-451.

董明灿.基于数据挖掘分析中医药治疗难治性胃食管反流病的辨证用药规律［D］.武汉：湖北中医药大学，2021

ASAOKA D，NAGAHARA A，HOJO M，et al.Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis，non-erosive reflux disease，and functional dyspepsia［J］.Biomed Rep，2017，6（2）：175-180.

中华医学会消化病学分会.2020年中国胃食管反流病专家共识［J］.中华消化杂志，2020，40（10）：649-663.

REY E，BARCELÓ M，ZAPARDIEL J，et al.Is the reflux disease questionnaire useful for identifying GERD according to the Montreal definition？［J］.BMC Gastroenterol，2014，14：17.

郑筱萸.中药新药临床研究指导原则［M］.北京：中国医药科技出版社，2002：53-66.

BLACKETT K L，SIDDHI S S，CLEARY S，et al.Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease，Barrett's and oesophageal carcinoma：Association or causality？［J］ .Aliment Pharmacol Ther，2013，37（11）：1084-1092.

庄琦，毛家亮，李春波，等.躯体化症状自评量表的初步编制及信度和效度研究［J］.中华行为医学与脑科学杂志，2010，19（9）：847-849.

刘思德，姜泊，周殿元.胃食管反流病内镜诊断标准及图片解读［J］.现代消化及介入诊疗，2008，13（1）：42-44.

LUNDELL L R，DENT J，BENNETT J R，et al.Endoscopic assessment of oesophagitis：Clinical and functional correlates and further validation of the Los Angeles classification［J］.Gut，1999，45（2）：172-180.

PATEL V，MA S，YADLAPATI R.Salivary biomarkers and esophageal disorders［J］.Dis Esophagus，2022，35（7）：doac018.

苏坤涵，刘万里.从脏腑气机升降论治难治性胃食管反流病［J］.中国中医急症，2020，29（7）：1224-1227.

董海影，张静艳，柏青杨，等.柴胡皂苷A对抑郁模型大鼠海马神经细胞凋亡的保护作用［J］.中国老年学杂志，2015，35（7）：1935-1937.

史永平，孔浩天，李昊楠，等.栀子的化学成分、药理作用研究进展及质量标志物预测分析［J］.中草药，2019，50（2）：281-289.

付琳，付强，李冀，等.黄连化学成分及药理作用研究进展［J］.中医药学报，2021，49（2）：87-92.

KAHRILAS P J，JONSSON A，DENISON H，et al.Concomitant symptoms itemized in the reflux disease questionnaire are associated with attenuated heartburn response to acid suppression［J］.Am J Gastroenterol，2012，107（9）：1354-1360.

JANUSZEWICZ W，HARTLEY J，WALDOCK W，et al.Endoscopic measurement of gastric pH associates with persistent acid reflux in patients treated with proton-pump inhibitors for gastroesophageal reflux disease［J］.United European Gastroenterol J，2019，7（10）：1389-1398.

NING H J，MA X，ZHU D，et al.Diagnostic value and application of 24 h multichannel intraluminal impedance-pH monitoring in children with gastroesophageal reflux disease［J］.Chin J Pediat，2022，60（12）：1312-1316.

LI N，CHEN Q，WEN S，et al.Diagnostic accuracy of multichannel intraluminal impedance-pH monitoring for gastroesophageal reflux-induced chronic cough［J］.Chron Respir Dis，2021，18：14799731211006682.

VARDAR R，KESKIN M.Indications of 24-h esophageal pH monitoring，capsule pH monitoring，combined pH monitoring with multichannel impedance，esophageal manometry，radiology and scintigraphy in gastroesophageal reflux disease？［J］.Turk J Gastroenterol，2017，28（Suppl 1）：S16-S21.

DE BORTOLI N，MARTINUCCI I，BERTANI L，et al.Esophageal testing：What we have so far［J］.World J Gastrointest Pathophysiol，2016，7（1）：72-85.

YADLAPATI R.High-resolution esophageal manometry：Interpretation in clinical practice［J］.Curr Opin Gastroenterol，2017，33（4）：301-309.

JEHANGIR A，MALIK Z，PARKMAN H P.Characterizing reflux on high resolution esophageal manometry with impedance［J］.BMC Gastroenterol，2022，22（1）：112.

VELANOVICH V.25 Years of the GERD-HRQL symptom severity instrument：An assessment of published applications［J］.Surg Endosc，2023，37（1）：255-265.

KOTHARI B L，BORGERT A J，KALLIES K J，et al.Lack of correlation between subjective and objective measures of gastroesophageal reflux disease：Call for a novel validated assessment tool［J］.Surg Innov，2021，28（3）：290-294.

HILL C，VERSLUIJS Y，FURAY E，et al.Psychoemotional factors and their influence on the quality of life in patients with GERD［J］.Surg Endosc，2021，35（12）：7219-7226.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Discussion on Development Status of Traditional Chinese Medicine Dispensing Granules and Survival Strategy of Enterprises

Medication Analysis of Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Allergic Rhinitis Based on Clinical Efficacy Evaluation

Design and Challenges of Real World Data as Control Group in A Randomized Controlled Trial of Chinese Medicine

The Influence of Sancaojangya Decoction on Signs and Behavioral Indexes of Spontaneous Hypertensive Rat

Related Author

YAN Xinjia

ZHOU Houcheng

LI Wenbing

CHEN Shilin

YANG Zhengming

LI Yaohong

LIU Shuqi

WANG Tao

Related Institution

Key Laboratory of Qinghai-Xizang Plateau Ethnic Medicinal Resources Protection and Utilization of National Ethnic Affairs Commission，Sichuan Engineering Laboratory of Qiang-Yi Medicinal Resources Protection and Utilization Technology，Southwest Minzu University

The Third People's Hospital of Bijie City

Sichuan Neo-green Pharmaceutical Technology Development Co. Ltd.，Pengzhou

Chengdu University of Traditional Chinese Medicine

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰